China approves commercial invasive BCI
News aggregators flagged that China granted the world's first commercial approval for an invasive brain‑computer interface to restore hand movement, a regulatory milestone that could accelerate global neurotech commercialization paths and influence U.S. device strategies reported. The move signals regulators are willing to greenlight high‑risk neurodevices in a commercial setting—potentially shifting competitive dynamics for neuromodulation players.
Neuracle Medical Technology — operating under the trade name Borui Kang — registered its Implantable Brain Computer Interface for Hand Motor Augmentation with China’s National Medical Products Administration on March 13, 2026. english.news.cn The system uses a minimally invasive epidural implant that wirelessly transmits decoded cortical signals to a pneumatic glove for grasping tasks, with the device architecture and glove control described in the NMPA clearance summary. news.cgtn.com Company and trial materials report a multi‑center GCP registration study that implanted 32 cervical spinal‑injury patients with cumulative implant days exceeding 7,000 and no device‑related serious adverse events, with investigators reporting 100% achievement of home brain‑controlled grasp in enrolled cases. news.qq.com Reporting on the approval shows some variance in cohort counts (other outlets cited 36 patients) and notes the device’s prior entry into the NMPA’s innovative‑medical‑device special review channel in August 2024, while related market moves included a stock uptick and a 500 million yuan fundraising round led by Alibaba for fellow Chinese neurotech firm StairMed. bloomberg.com
